the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines

NCT07338851 · tracked via the Priya Life Science China tracker

Sponsor

China National Biotec Group Company Limited

Phase

Observational

Started

2026-01-30

Last updated

2026-01-14

Condition(s) studied

PolioMeaslesRubellaMumpsHepatitis A

Study summary

This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Participants in the NCT04638985 or NCT04636827, and who have completed the vaccination of designated batch numbers of sIPV, MMR or HepA-L vaccines; * The time window from the day of enrollment to the date when the participants received the fourth dose of sIPV vaccine, the second dose of MMR vaccine, or the first dose of HepA-L vaccine was 60 to 66 months. * The informed consent form shall be signed by the participant or his/her legal guardian and dated. Exclusion Criteria: * None.

Primary outcome measure(s)

seropositive rates of antibodies against poliovirus — 5 years after the four doses of sIPV immunization
The percentage of participants with positive antibody(titre ≥ 8) against all three serotypes of poliovirus 5 years after the four doses of sIPV immunization.
seropositive rates of antibodies against measles, rubella, mumps — 5 years after the two doses of MMR immunization
The percentage of participants with positive antibody against measles, rubella, mumps 5 years after the two doses of MMR immunization.
seropositive rates of antibodies against hepatitis A — 5 years after the one doses of HepA-L immunization
The percentage of participants with positive antibody against hepatitis A 5 years after the one doses of HepA-L immunization.

Trial sites (6)

Facility	City	Region
Si County Center for Disease Control and Prevention	Suzhou	Anhui
Feixiang District Center for Disease Control and Prevention	Handan	Hebei
Sheyang County Center for Disease Control and Prevention	Yancheng	Jiangsu
Chenggu County Center for Disease Control and Prevention	Hanzhong	Shaanxi
Yanhu District Center for Disease Control and Prevention	Yuncheng	Shanxi
Jiangyou Center for Disease Control and Prevention	Mianyang	Sichuan

More China National Biotec Group Company Limited trials in China

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. Recruiting

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed Active, not recruiting

Other trials for the same condition

Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old Active, not recruiting

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age Starting soon

Study of Concomitant Administration of the sIPV and DTaP or MMR Starting soon

Phase IV Study of Concomitant Administration of the sIPV and HepA Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07338851 on ClinicalTrials.gov ↗ ← All trials in China